New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Wired.